(HealthDay)—Xgeva (denosumab) has been approved by the U.S. Food and Drug Administration to treat giant cell tumor of the bone (GCTB), a rare tumor that's most often non-cancerous.
Jun 13, 2013
0
0
Amgen Inc. cruised to a 27 percent jump in fourth-quarter profit and beat Wall Street expectations, due to higher sales of nearly all its medicines, tight cost controls and a tax benefit.
Jan 27, 2015
0
2
Swiss drug maker Novartis says it will cooperate with California-based biotech giant Amgen to develop and sell neuroscience treatments for illnesses and ailments like Alzheimer's disease and migraine headaches.
Sep 2, 2015
0
12
US pharmaceutical giant Amgen has pleaded guilty to illegally introducing a mislabeled drug for treating anemia onto the market and will pay a record $762 million fine, officials said Wednesday.
Dec 18, 2012
0
0
The US Supreme Court ruled Wednesday in favor of investors seeking to join a class-action lawsuit against pharmaceutical giant Amgen for downplaying safety concerns about two anemia drugs.
Feb 28, 2013
0
0
Biotech pioneer Amgen Inc., in a bid for a big edge in using people's genetic information to find better ways to attack diseases, is buying human genetics research and analytics leader deCODE Genetics for $415 million.
Dec 10, 2012
0
0
U.S. government health regulators have halted Amgen's studies of its drug Sensipar after the death of a 14-year-old patient in a company trial.
Feb 26, 2013
0
0
Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed Wall Street's ...
Apr 22, 2014
0
0
Amgen Inc.'s fourth-quarter profit jumped 30 percent due to higher sales for nearly all its drugs, an acquisition and a tax benefit.
Jan 28, 2014
0
0
